He is still doing great to be doing as well as he is.
A lot to be seen yet, but he stepping big up to plate of being the 2nd RedBull driver.

She lacks the character, experience and independence required for the job and on day 1 has shown why someone needs all 3.

So the report is actually saying you won’t be able to sit on this like other medical developments so you will need to innovate more or target markets carefully.

This is a big difference to
“Why heal people if that stops us making money”

“Solution 3: Constant innovation and portfolio expansion: There are hundreds of inherited retinal diseases (genetics forms of blindness) … Pace of innovation will also play a role as future programs can offset the declining revenue trajectory of prior assets.”

“Solution 2: Address disorders with high incidence: Spinal muscular atrophy (SMA) affects the cells (neurons) in the spinal cord, impacting the ability to walk, eat, or breathe.”

The report suggested three potential solutions for biotech firms:

“Solution 1: Address large markets: Hemophilia is a $9-10bn WW market (hemophilia A, B), growing at ~6-7% annually.”

A lot of people here missing the conclusion of the report.
Which I will list below.
Quote directly from the end of the article.